MCID: GST040
MIFTS: 52

Gastric Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

Aliases & Descriptions for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 14 69
Adenocarcinoma of Stomach 12
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3717
NCIt 47 C4004
SNOMED-CT 64 408647009
UMLS 69 C0278701

Summaries for Gastric Adenocarcinoma

Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric adenocarcinoma and proximal polyposis of the stomach and gastric cardia adenocarcinoma, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are WNT Signaling and Pathways in cancer. The drugs Taxotere and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, breast and endothelial, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Related Diseases for Gastric Adenocarcinoma

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
id Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma and proximal polyposis of the stomach 11.9
2 gastric cardia adenocarcinoma 11.3
3 gastric cancer risk after h. pylori infection 11.1
4 adenocarcinoma 11.0
5 krukenberg carcinoma 10.9
6 gastric papillary adenocarcinoma 10.9
7 gastric tubular adenocarcinoma 10.9
8 mucinous stomach adenocarcinoma 10.8
9 gastric signet ring cell adenocarcinoma 10.8
10 substance abuse 10.4 CDH1 CTNNB1 ERBB2
11 reactive arthritis 10.4 CTNNB1 ERBB2 PTGS2
12 nemaline myopathy 8, autosomal recessive 10.3 CDH1 CTNNB1 ERBB2
13 basaloid squamous cell carcinoma 10.3 CDH1 CEACAM5 ERBB2
14 adult myxoid chondrosarcoma 10.3 CTNNB1 KRT20
15 autoimmune pancreatitis 10.3 CHGA GAST
16 bone giant cell tumor 10.3 ERBB2 MYC
17 acquired hemangioma 10.3 CDX2 ERBB2 PTGS2
18 vagneur triolle ripert syndrome 10.3 CEACAM5 CHGA
19 pulmonary artery choriocarcinoma 10.3 CEACAM5 ERBB2
20 macrocytic anemia 10.3 CEACAM5 CTNNB1 PTGS2
21 gastrointestinal system cancer 10.3 CDH1 CEACAM5 ERBB2
22 vacterl association with hydrocephaly, x-linked 10.3 AFP CEACAM5
23 ehlers-danlos syndrome, type viic 10.3 CDH1 CTNNB1 MYC
24 ovarian mucinous neoplasm 10.3 CDX2 GAST PTGS2
25 spastic diplegia infantile type 10.3 CDX2 CTNNB1 ERBB2
26 vulvar keratoacanthoma-like carcinoma 10.3 CEACAM5 CHGA
27 vulva squamous cell carcinoma 10.3 CEACAM5 ERBB2 KRT20
28 thymoma 10.3 CDX2 CEACAM5 GAST
29 neuroendocrine tumor 10.3 CDX2 KRT20 PTGS2
30 dental caries 10.3 CDH1 CEACAM5 ERBB2
31 rete testis adenoma 10.3 AFP CEACAM5
32 nasal cavity disease 10.3 CDH1 CEACAM5 ERBB2
33 sarcomatoid basal cell carcinoma 10.3 CDH1 CEACAM5 KRT20
34 progesterone-receptor positive breast cancer 10.3 CDH1 ERBB2 PTGS2
35 uterine corpus endometrial stromal sarcoma 10.3 CEACAM5 KRT20 MLH1
36 lattice corneal dystrophy 10.3 ERBB2 MLH1 PTGS2
37 breast cystic hypersecretory carcinoma 10.3 GAST PTGS2 S100A8
38 glossopharyngeal motor neuropathy 10.3 CDH1 ERBB2
39 prostatic adenoma 10.3 CTNNB1 ERBB2 MLH1
40 vipoma 10.3 AFP CHGA
41 myotonic disease 10.3 CDH1 CEACAM5 KRT20
42 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.3 CDX2 GAST PTGS2
43 secondary syphilis 10.3 CHGA GAST
44 apocrine adenocarcinoma 10.3 CDX2 CEACAM5 KRT20
45 congenital symblepharon 10.3 CTNNB1 MLH1 PTGS2
46 bladder carcinoma in situ 10.3 AFP CEACAM5
47 brain edema 10.3 CHGA GAST
48 dysembryoplastic neuroepithelial tumor 10.3 CDH1 ERBB2 KRT20 PTGS2
49 neuroretinitis 10.3 CDX2 KRT20 MLH1
50 papillary adenofibroma 10.3 CDX2 CEACAM5 KRT20

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 ERBB2 FHIT GAST MLH1 MYC PTGS2
2 digestive/alimentary MP:0005381 10.14 CCKBR CDH1 CDX2 CTNNB1 ERBB2 FHIT
3 endocrine/exocrine gland MP:0005379 10.11 AFP CCKBR CDH1 CDX2 CHGA CTNNB1
4 mortality/aging MP:0010768 9.97 AFP CDH1 CDX2 CHGA CLDN4 CTNNB1
5 integument MP:0010771 9.91 CCKBR CDH1 CTNNB1 CTSE ERBB2 FHIT
6 neoplasm MP:0002006 9.7 CDX2 CTNNB1 ERBB2 FHIT GAST MLH1
7 reproductive system MP:0005389 9.36 AFP CDH1 CDX2 CHGA CTNNB1 CTSE

Drugs & Therapeutics for Gastric Adenocarcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer Approved May 1996

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
2
Clarithromycin Approved Phase 4 81103-11-9 84029
3
Metronidazole Approved Phase 4,Phase 1 443-48-1 4173
4
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
7
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
8
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
9
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
10
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
11
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
12
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
13
Nicotine Approved Phase 4 54-11-5 942 89594
14
Somatostatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 38916-34-6, 51110-01-1 53481605
15
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
16
Iron Approved Phase 4 7439-89-6 23925
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
19
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antiparasitic Agents Phase 4,Phase 2,Phase 1
23 Antiprotozoal Agents Phase 4,Phase 2,Phase 1
24 Cytochrome P-450 CYP3A Inhibitors Phase 4
25 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
26 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
27 Adrenergic Agents Phase 4
28 Adrenergic Antagonists Phase 4
29 Adrenergic beta-Antagonists Phase 4
30 Anti-Arrhythmia Agents Phase 4
31 Antihypertensive Agents Phase 4
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
33 Vasodilator Agents Phase 4
34 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
37 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
38 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
40 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2
41 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2
42 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
43 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2
47 Vitamins Phase 4,Phase 3,Phase 1,Phase 2
48
Lactitol Phase 4,Phase 1,Phase 2 585-86-4 3871
49 Antacids Phase 4,Phase 3,Phase 2
50 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 683)
id Name Status NCT ID Phase
1 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
3 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4
4 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4
5 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4
6 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4
7 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4
8 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
9 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
10 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Recruiting NCT02426034 Phase 4
11 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4
12 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4
13 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
14 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
15 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
16 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4
17 Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Terminated NCT00871273 Phase 4
18 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4
19 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
20 Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Unknown status NCT01015339 Phase 3
21 Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction Unknown status NCT01468389 Phase 3
22 SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer Unknown status NCT01583361 Phase 3
23 Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer Unknown status NCT01283217 Phase 3
24 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3
25 Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus Unknown status NCT00987857 Phase 3
26 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3
27 Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma Completed NCT00323830 Phase 3
28 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3
29 Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction Completed NCT01646476 Phase 3
30 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3
31 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296335 Phase 3
32 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296322 Phase 3
33 A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer Completed NCT02560974 Phase 3
34 Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer Completed NCT00411229 Phase 3
35 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3
36 Metastatic Gastric Cancer FFCD 03-07 Completed NCT00374036 Phase 3
37 S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer Completed NCT00182611 Phase 3
38 A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer Completed NCT01662869 Phase 3
39 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Completed NCT00002615 Phase 3
40 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3
41 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed NCT00879333 Phase 3
42 Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma Completed NCT01491698 Phase 3
43 A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer Completed NCT00548548 Phase 3
44 Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma Completed NCT02445209 Phase 3
45 Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer Completed NCT00260884 Phase 3
46 A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum Completed NCT00145769 Phase 3
47 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3
48 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3
49 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3
50 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3

Search NIH Clinical Center for Gastric Adenocarcinoma

Genetic Tests for Gastric Adenocarcinoma

Anatomical Context for Gastric Adenocarcinoma

MalaCards organs/tissues related to Gastric Adenocarcinoma:

39
Lymph Node, Breast, Endothelial, Colon, Liver, Lung, T Cells

Publications for Gastric Adenocarcinoma

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 1037)
id Title Authors Year
1
Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. ( 28044374 )
2017
2
Prognostic significance of autophagy-related proteins expression in resected human gastric adenocarcinoma. ( 28224423 )
2017
3
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas. ( 26567008 )
2017
4
Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma. ( 28035352 )
2017
5
Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome. ( 28501935 )
2017
6
Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma. ( 27943102 )
2017
7
MALAT1 promoted invasiveness of gastric adenocarcinoma. ( 28077118 )
2017
8
CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2. ( 28029907 )
2017
9
Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma. ( 27584713 )
2016
10
Efficacy of Omega Fatty Acid Supplementation on mRNA Expression Level of Tumor Necrosis Factor Alpha in Patients with Gastric Adenocarcinoma. ( 27170003 )
2016
11
Concomitant multiple myeloma, gastric adenocarcinoma and Evan's syndrome in a patient presenting with anaemia. ( 27979847 )
2016
12
SNP rs1059234 in CDKN1A Gene Correlates with Prognosis in Resected Gastric Adenocarcinoma. ( 27156331 )
2016
13
Clinicopathological Features of Gastric Adenocarcinoma of the Fundic Gland (Chief Cell Predominant Type) by Retrospective and Prospective Analyses of Endoscopic Findings. ( 27129734 )
2016
14
Decreased Dp71 expression is associated with gastric adenocarcinoma prognosis. ( 27449096 )
2016
15
Elevated expression of Nodal and YAP1 is associated with poor prognosis of gastric adenocarcinoma. ( 27325246 )
2016
16
Nuclear overexpression of the overexpressed in lung cancer 1 predicts worse prognosis in gastric adenocarcinoma. ( 28038462 )
2016
17
Tumor volume of resectable gastric adenocarcinoma on multidetector computed tomography: association with N categories. ( 27166769 )
2016
18
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). ( 27602586 )
2016
19
Gastric adenocarcinoma of the fundic gland (chief cell-predominant type): A review of endoscopic and clinicopathological features. ( 28082804 )
2016
20
Gastric Adenocarcinoma Presenting after Revisional Roux-en-Y Gastric Bypass. ( 27657561 )
2016
21
Clinical significance of I^2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. ( 27485115 )
2016
22
Gastric Adenocarcinoma in a Patient with X-Linked Agammaglobulinemia and HIV: Case Report and Review of the Literature. ( 27722150 )
2016
23
Epigenetic changes of CDX2 in gastric adenocarcinoma. ( 27139434 )
2016
24
Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. ( 26887337 )
2016
25
Growth inhibition of human gastric adenocarcinoma cells in vitro by STO-609 is independent of calcium/calmodulin-dependent protein kinase kinase-beta and adenosine monophosphate-activated protein kinase. ( 27158402 )
2016
26
Gastric Adenocarcinoma of the Fundic Gland Type Treated by Endoscopic Mucosal Resection: A Case Report and Review of the Literature. ( 27994902 )
2016
27
Beyond gastric adenocarcinoma: Multimodality assessment of common and uncommon gastric neoplasms. ( 27645897 )
2016
28
The Value of Preoperative Neutrophil to Lymphocyte Ratio in Indicating Lymph Node Metastasis in Patients with Resectable T2 Stage Gastric Adenocarcinoma. ( 27215086 )
2016
29
Presence of Epstein-Barr virus in gastric adenocarcinoma in Indian patients. ( 27514983 )
2016
30
Clinicopathological characteristics and outcomes in stage I-III mucinous gastric adenocarcinoma: a retrospective study at a single medical center. ( 27112436 )
2016
31
Twelve-year natural history of a gastric adenocarcinoma of fundic gland type. ( 27624750 )
2016
32
Germ Cell Tumor Targeting Chemotherapy in Gastric Adenocarcinoma with an Endodermal Sinus Tumor Component: A Case Report. ( 27351795 )
2016
33
The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review ofA the literature. ( 27343414 )
2016
34
Dual-Tracer PET/CT Using 18F-FDG and 11C-Acetate in Gastric Adenocarcinoma With Liver Metastasis. ( 27648704 )
2016
35
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. ( 27478410 )
2016
36
EXPRESSION OF E-CADHERIN AND WNT PATHWAY PROTEINS BETACATENIN, APC, TCF-4 AND SURVIVIN IN GASTRIC ADENOCARCINOMA: CLINICAL AND PATHOLOGICAL IMPLICATION. ( 28076475 )
2016
37
The overexpression of MDM4: an effective and novel predictor of gastric adenocarcinoma lymph node metastasis. ( 27626496 )
2016
38
Concurrent Gastric Adenocarcinoma of Fundic Gland Type and Carcinoma with Lymphoid Stroma: A Rare Case Report. ( 27462199 )
2016
39
Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. ( 27249691 )
2016
40
Increased MACC1 expression indicates a poor prognosis independent of MET expression in gastric adenocarcinoma. ( 26719224 )
2016
41
Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma. ( 26611647 )
2016
42
microRNA-25 Inhibits Cell Apoptosis of Human Gastric Adenocarcinoma Cell Line AGS via Regulating CCNE1 and MYC. ( 27120728 )
2016
43
High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma. ( 27012044 )
2016
44
A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population. ( 26818920 )
2016
45
The role of the obestatin/GPR39 system in human gastric adenocarcinomas. ( 26716511 )
2016
46
DELAYED-ONSET BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION ASSOCIATED WITH GASTRIC ADENOCARCINOMA. ( 27662408 )
2016
47
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. ( 27467911 )
2016
48
Helicobacter pylori-negative early gastric adenocarcinoma with complete intestinal mucus phenotype mimicking verrucous gastritis. ( 27977882 )
2016
49
The expression of metastasis-associated in colon cancer-1 and KAI1 in gastric adenocarcinoma and their clinical significance. ( 27793161 )
2016
50
Gastric adenocarcinoma concurrent with paravertebral plasmacytoma: A case report. ( 27446469 )
2016

Variations for Gastric Adenocarcinoma

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6 (show top 50) (show all 94)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
3 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
9 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
10 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
11 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
12 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
15 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
17 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
18 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
19 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
20 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
21 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic/Likely pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
22 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
23 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
24 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
25 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
26 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
27 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
28 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
29 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
30 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
31 ERBB2 NM_001005862.2(ERBB2): c.2236G> A (p.Gly746Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933369 GRCh37 Chromosome 17, 37880997: 37880997
32 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
33 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
34 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
35 RAF1 NM_002880.3(RAF1): c.770C> T (p.Ser257Leu) single nucleotide variant Pathogenic/Likely pathogenic rs80338796 GRCh37 Chromosome 3, 12645699: 12645699
36 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
37 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
38 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
39 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
40 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
41 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
42 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
43 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
44 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
45 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
46 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
47 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
48 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
49 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
50 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain C1orf88 Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain SPFH1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain ST5 Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss KIAA0179 Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma

Expression for Gastric Adenocarcinoma

Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for Gastric Adenocarcinoma

GO Terms for Gastric Adenocarcinoma

Cellular components related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical junction complex GO:0043296 9.26 CDH1 CTNNB1
2 catenin complex GO:0016342 9.16 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
4 lateral plasma membrane GO:0016328 8.8 CDH1 CLDN4 CTNNB1

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.72 CCKBR CDX2 CTNNB1 MYC PTGS2
2 wound healing GO:0042060 9.58 ERBB2 S100A8 TFF1
3 ovulation GO:0030728 9.37 MYC PTGS2
4 cell proliferation GO:0008283 9.35 CCKBR CTNNB1 ERBB2 MYC ROS1
5 digestion GO:0007586 9.33 CCKBR CTSE TFF1
6 entry of bacterium into host cell GO:0035635 9.26 CDH1 CTNNB1
7 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNB1

Molecular functions related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 CTNNB1 ERBB2 ROS1

Sources for Gastric Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....